LNTH
Lantheus Holdings, Inc.
73.81
USD
This page is just a preview of the data found in TrendSpider’s full version
Lantheus Holdings, Inc. stock is up 14.75% since 30 days ago. The next earnings date is Feb 22, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 33.33% of the previous 8 December’s closed higher than November. In the last 10 Unusual Options Trades, there were 10 CALLs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 01 Dec 15:05 | 19 Jan, 2024 | 75.00 | 2798 | ||
| 01 Dec 17:17 | 19 Jan, 2024 | 75.00 | 2798 | ||
| 01 Dec 17:29 | 19 Jan, 2024 | 70.00 | 3753 | ||
| 01 Dec 17:43 | 19 Jan, 2024 | 70.00 | 3753 | ||
| 01 Dec 19:42 | 19 Jan, 2024 | 85.00 | 637 | ||
| 01 Dec 19:55 | 15 Dec, 2023 | 70.00 | 3176 | ||
| 01 Dec 20:07 | 19 Jan, 2024 | 70.00 | 3753 | ||
| 01 Dec 20:17 | 19 Jan, 2024 | 70.00 | 3753 | ||
| 01 Dec 20:17 | 19 Jan, 2024 | 70.00 | 3753 | ||
| 01 Dec 20:17 | 19 Jan, 2024 | 70.00 | 3753 |
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases. It provides DEFINITY, a microbubble ultrasound enhancing agent used in ultrasound exams of the heart. The company also offers AZEDRA, a radiotherapeutic to treat adult and pediatric patients; Automated Bone Scan Index that calculates disease burden of prostate cancer by quantifying the hotspots on bone scans.
